

Fig. 1




Fig. 2

A

<i>species</i>		1.....20
<i>Homo sapiens</i>	(NP_057632.2)	SSRSVDLQTRIMELEGRVRR
<i>Canis familiaris</i>	(XP_533506.2)	SSRSVDLQTRIVELEGRVRR
<i>Mus musculus</i>	(NP_081583.3)	SSRSV E LQTRIVELEGRVRR

B

<i>Homo sapiens</i>	(NP_057632.2)	21/21	
<i>Canis familiaris</i>	(XP_533506.2)	20/21; 95%	
<i>Bos taurus</i>	(NP_001179392.1)	20/21; 95%	
<i>Mus musculus</i>	(NP_081583.3)	19/21; 90%	
<i>Danio rerio</i>	(XP_699743.3)	20/21; 95%	
<i>Gallus gallus</i>	(XP_425035.2)	18/21; 86%	
<i>Pan troglodytes</i>	(XP_520104.6)	21/21; 100%	
<i>Rattus norvegicus</i>	(XP_001056825.3)	19/21; 90%	




Fig. 3A




Fig. 3B




Fig. 3C






Fig. 3D



A



B

Fig. 4

Fig. 5





Fig.6






Fig. 7

Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13A

HuH7





Fig. 13 B



- A: G2-1 (2mg/ml)
 B: Cetuximab (2mg/ml)
 C: G2-1+Cetuximab (1mg/ml each)
 D: Bevacizumab+Cetuximab (1mg/ml each)
 E: Bevacizumab (2mg/ml)

Fig. 14

HuH7




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21 A




Fig. 21 B




Fig. 21 C




Fig. 22 A




Fig. 22 B




Fig. 22 C




Fig. 23




Fig. 24

